Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Waldenstrom Macroglobulinemia 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Fallopian Tube Neoplasms 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1

Interventions

regorafenib 1ivosidenib 1durvalumab 1Zoledronic Acid 1Proton Therapy 1Pharmacogenomic Testing 1HhAntag691 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Chondrosarcoma × Pharmacogenomic Testing × Clear all
NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
45 enrolled 10 charts
Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡